• Publications
  • Influence
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TLDR
It is suggested that the neoadjuvant administration of PD-1 blockade enhances both the local and systemic antitumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor. Expand
Glioma Subclassifications and Their Clinical Significance
TLDR
This review aims to summarize the current literature regarding glioma subclassifications and their clinical relevance in this evolving field and provides the essential framework for the development and testing of new specific targeted therapies for particular gliomas subtypes. Expand
Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP
TLDR
It is demonstrated that the transcription factor c-Myc drives glucose metabolism in TNBC cells but does so by a previously unappreciated mechanism that involves direct repression of thioredoxin-interacting protein (TXNIP). Expand
Glioma biology and molecular markers.
TLDR
The tumors classified as gliomas include a wide variety of histologies including the more common (astrocytoma, glioblastoma), as well as the less common histologies (oligodendrogliomas), which can be further characterized based on gene expression and gene methylation patterns into three or four distinct subgroups. Expand
Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
TLDR
In this large registry study, there was no difference in survival in patients with GBM compared with GS, and among GS patients, trimodality therapy significantly improved survival compared with nontrimodality Therapy. Expand
IDH1 and IDH2 Mutations in Gliomas
TLDR
Gliomas with mutated IDH1 and IDH2 have improved prognosis compared with gliomas with wild-type IDH, and can now be detected by immunohistochemistry and magnetic resonance spectroscopy. Expand
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
TLDR
High-grade gliomas remain incurable despite current therapies, and novel combinatorial therapy or targeted drugs with immunomodulatory or epigenetic approaches will likely be necessary to successfully combat these challenging tumors. Expand
Combating subclonal evolution of resistant cancer phenotypes
TLDR
The genetic and phenotypic subclonal evolution of four breast cancers through years of treatment is tracked to better understand how breast cancers become drug-resistant and suggest a phenotype-targeted treatment strategy to adapt to cancer as it evolves. Expand
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
TLDR
The role of several key players in glioma classification and biology, namely isocitrate dehydrogenase 1 and 2, alpha thalassemia/mental retardation syndrome X-linked, ATRX, B-Raf, telomerase reverse transcriptase (TERT), telomere maintenance in gliomagenesis, and H3K27M are discussed. Expand
DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status
TLDR
The data support the novel findings that malignant progression of IDHmut gliomas to GBM involves increased genomic instability and genomic catastrophe, while IDHwt lower grade tumors are virtually identical to GBMs at the level of DNA copy number alterations. Expand
...
1
2
3
4
5
...